Epidemiology of lung cancer in korea: Recent trends

Tuberculosis and Respiratory Diseases

Volumn 79, Issue 2, 2016, Pages 58-69

  Park, Ji Young ^a   Jang, Seung Hun ^b  

^a The Armed Forces Daejeon Hospital   (South Korea)

^b Hallym University   (South Korea)

Author keywords

Incidence; Korea; Lung neoplasms; Mortality; Prevalence; Survival

Indexed keywords

TOBACCO SMOKE;

AIR POLLUTION; CANCER INCIDENCE; CANCER SURVIVAL; CHRONIC LUNG DISEASE; GENE; HUMAN; KOREA; LUNG ADENOCARCINOMA; LUNG CANCER; MOLECULAR EPIDEMIOLOGY; MORTALITY RATE; MUTATION; REGISTER; REVIEW; RISK FACTOR; SMOKING; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

EID: 84964350752     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2016.79.2.58     Document Type: Review

References (74)

1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The global burden of cancer 2013. JAMA Oncol 2015;1:505-27.
2. Korea Central Cancer Registry. Annual report of cancer statistics in Korea in 2012 [Internet]. Goyang: National Cancer Information Center; 2015 [cited 2015 Mar 31]. Available from: http://www.cancer.go.kr/.
3. In KH, Kwon YS, Oh IJ, Kim KS, Jung MH, Lee KH, et al. Lung cancer patients who are asymptomatic at diagnosis show favorable prognosis: A Korean Lung Cancer Registry Study. Lung Cancer 2009;64:232-7.
4. Park JH, Lee KS, Choi KS. Burden of cancer in Korea during 2000-2020. Cancer Epidemiol 2013;37:353-9.
5. World DataBank. World development indicators [Internet]. Washington, DC: The World Bank Group; 2015 [cited 2015 Nov 11]. Available from: http://databank.worldbank.org/ddp/home.do.
6. Planchard D, Besse B. Lung cancer in never-smokers. Eur Respir J 2015;45:1214-7.
7. Wakelee HA, Chang ET, Gomez SL, Keegan TH, Feskanich D, Clarke CA, et al. Lung cancer incidence in never smokers. J Clin Oncol 2007;25:472-8.
8. Kang H, Park CW, Kim W, Song SY, Na KJ, Jeong JU, et al. Never- smoker lung cancer is increasing. J Lung Cancer 2012;11: 89-93.
9. Couraud S, Souquet PJ, Paris C, Do P, Doubre H, Pichon E, et al. BioCAST/IFCT-1002: Epidemiological and molecular features of lung cancer in never-smokers. Eur Respir J 2015;45: 1403-14.
10. Ha SY, Choi SJ, Cho JH, Choi HJ, Lee J, Jung K, et al. Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR. Oncotarget 2015;6: 5465-74.
11. Korean Statistical Information Service. Statistics Korea [Internet]. Daejeon: Statistics Korea; 2015 [cited 2015 Sep 23]. Available from: http://kosis.kr/.
12. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003;8:541-52.
13. Lortet-Tieulent J, Soerjomataram I, Ferlay J, Rutherford M, Weiderpass E, Bray F. International trends in lung cancer incidence by histological subtype: Adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer 2014;84:13- 22.
14. Zhou C. Lung cancer molecular epidemiology in China: Recent trends. Transl Lung Cancer Res 2014;3:270-9.
15. Toyoda Y, Nakayama T, Ioka A, Tsukuma H. Trends in lung cancer incidence by histological type in Osaka, Japan. Jpn J Clin Oncol 2008;38:534-9.
16. Gray N. The consequences of the unregulated cigarette. Tob Control 2006;15:405-8.
17. Marugame T, Sobue T, Nakayama T, Suzuki T, Kuniyoshi H, Sunagawa K, et al. Filter cigarette smoking and lung cancer risk: A hospital-based case: control study in Japan. Br J Cancer 2004;90:646-51.
18. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: Epidemiology, etiology, and prevention. Clin Chest Med 2011;32:605- 44.
19. Kenfield SA, Wei EK, Stampfer MJ, Rosner BA, Colditz GA. Comparison of aspects of smoking among the four histological types of lung cancer. Tob Control 2008;17:198-204.
20. Ahn MJ, Lee J, Park YH, Ahn JS, Ziogas A, Zell JA, et al. Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era. J Thorac Oncol 2010;5:1185-96.
21. Jung KW, Won YJ, Kong HJ, Oh CM, Cho H, Lee DH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat 2015;47:127-41.
22. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25, 676, 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015;385:977-1010.
23. Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e1S-29S.
24. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER cancer statistics review, 1975-2012. Bethesda: National Cancer Institute; 2015.
25. Donington JS, Colson YL. Sex and gender differences in nonsmall cell lung cancer. Semin Thorac Cardiovasc Surg 2011; 23:137-45.
26. Wang LE, Yin M, Dong Q, Stewart DJ, Merriman KW, Amos CI, et al. DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy. J Clin Oncol 2011;29:4121-8.
27. Soo RA, Loh M, Mok TS, Ou SH, Cho BC, Yeo WL, et al. Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: Results of a meta-analysis of randomized controlled trials. J Thorac Oncol 2011;6:1030-8.
28. Ou SH, Ziogas A, Zell JA. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol 2009;4:1083-93.
29. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A model for assessing population-related pharmacogenomics. J Clin Oncol 2009;27:3540-6.
30. Yun YH, Lim MK, Jung KW, Bae JM, Park SM, Shin SA, et al. Relative and absolute risks of cigarette smoking on major histologic types of lung cancer in Korean men. Cancer Epidemiol Biomarkers Prev 2005;14:2125-30.
31. Lee PN, Forey BA, Coombs KJ. Systematic review with metaanalysis of the epidemiological evidence in the 1900s relating smoking to lung cancer. BMC Cancer 2012;12:385.
32. Janjigian YY, McDonnell K, Kris MG, Shen R, Sima CS, Bach PB, et al. Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. Cancer 2010;116:670-5.
33. Kogure Y, Ando M, Saka H, Chiba Y, Yamamoto N, Asami K, et al. Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L. J Thorac Oncol 2013;8:753-8.
34. Yano T, Haro A, Shikada Y, Maruyama R, Maehara Y. Nonsmall cell lung cancer in never smokers as a representative 'non-smoking-associated lung cancer': Epidemiology and clinical features. Int J Clin Oncol 2011;16:287-93.
35. Couraud S, Zalcman G, Milleron B, Morin F, Souquet PJ. Lung cancer in never smokers: A review. Eur J Cancer 2012;48:1299- 311.
36. Bae JM. Modifiable risk factors of lung cancer in neversmoker women. Epidemiol Health 2015 Oct 29 [Epub]. http://dx.doi.org/10.4178/epih/e2015047.
37. Hackshaw AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ 1997; 315:980-8.
38. Zhong L, Goldberg MS, Parent ME, Hanley JA. Exposure to environmental tobacco smoke and the risk of lung cancer: A meta-analysis. Lung Cancer 2000;27:3-18.
39. Nordquist LT, Simon GR, Cantor A, Alberts WM, Bepler G. Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest 2004;126:347-51.
40. Quoix E, Monnet I, Scheid P, Hamadouche A, Chouaid C, Massard G, et al. Management and outcome of French elderly patients with lung cancer: An IFCT survey. Rev Mal Respir 2010;27:421-30.
41. Toh CK, Gao F, Lim WT, Leong SS, Fong KW, Yap SP, et al. Never-smokers with lung cancer: Epidemiologic evidence of a distinct disease entity. J Clin Oncol 2006;24:2245-51.
42. Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, et al. Gender, histology, and time of diagnosis are important factors for prognosis: Analysis of 1499 neversmokers with advanced non-small cell lung cancer in Japan. J Thorac Oncol 2010;5:1011-7.
43. Straif K, Cohen A, Samet J. Air pollution and cancer [Internet]. Lyon: International Agency for Research on Cancer; 2013 [cited 2015 Nov 11]. Available from: http://www.iarc.fr/en/publications/books/sp161/AirPollutionandCancer161.pdf.
44. Gallus S, Negri E, Boffetta P, McLaughlin JK, Bosetti C, La Vecchia C. European studies on long-term exposure to ambient particulate matter and lung cancer. Eur J Cancer Prev 2008; 17:191-4.
45. Katanoda K, Sobue T, Satoh H, Tajima K, Suzuki T, Nakatsuka H, et al. An association between long-term exposure to ambient air pollution and mortality from lung cancer and respiratory diseases in Japan. J Epidemiol 2011;21:132-43.
46. Hwang SS, Lee JH, Jung GW, Lim JH, Kwon HJ. Spatial analysis of air pollution and lung cancer incidence and mortality in 7 metropolitan cities in Korea. J Prev Med Public Health 2007; 40:233-8.
47. Sung JH, Cho SH, Kang DH, Yoo KY. Lung cancer, chronic obstructive pulmonary disease and air pollution. Korean J Prev Med 1997;30:585-98.
48. Desai MA, Mehta S, Smith KR. Indoor smoke from solid fuels: Assessing the environmental burden of disease at national and local levels [Internet]. Geneva: World Health Organization; 2004 [cited 2015 Nov 11.] Available from: http://www.who.int/quantifying-ehimpacts/publications/en/Indoorsmoke. pdf.
49. Lissowska J, Bardin-Mikolajczak A, Fletcher T, Zaridze D, Szeszenia-Dabrowska N, Rudnai P, et al. Lung cancer and indoor pollution from heating and cooking with solid fuels: The IARC international multicentre case-control study in Eastern/Central Europe and the United Kingdom. Am J Epidemiol 2005;162:326-33.
50. Zhao Y, Wang S, Aunan K, Seip HM, Hao J. Air pollution and lung cancer risks in China: A meta-analysis. Sci Total Environ 2006;366:500-13.
51. Yu IT, Chiu YL, Au JS, Wong TW, Tang JL. Dose-response relationship between cooking fumes exposures and lung cancer among Chinese nonsmoking women. Cancer Res 2006;66: 4961-7.
52. Kim C, Gao YT, Xiang YB, Barone-Adesi F, Zhang Y, Hosgood HD, et al. Home kitchen ventilation, cooking fuels, and lung cancer risk in a prospective cohort of never smoking women in Shanghai, China. Int J Cancer 2015;136:632-8.
53. Peek RM Jr, Mohla S, DuBois RN. Inflammation in the genesis and perpetuation of cancer: summary and recommendations from a national cancer institute-sponsored meeting. Cancer Res 2005;65:8583-6.
54. Brenner DR, Boffetta P, Duell EJ, Bickeboller H, Rosenberger A, McCormack V, et al. Previous lung diseases and lung cancer risk: A pooled analysis from the International Lung Cancer Consortium. Am J Epidemiol 2012;176:573-85.
55. Denholm R, Schuz J, Straif K, Stucker I, Jockel KH, Brenner DR, et al. Is previous respiratory disease a risk factor for lung cancer? Am J Respir Crit Care Med 2014;190:549-59.
56. Antoniou KM, Tomassetti S, Tsitoura E, Vancheri C. Idiopathic pulmonary fibrosis and lung cancer: A clinical and pathogenesis update. Curr Opin Pulm Med 2015;21:626-33.
57. Kwak N, Park CM, Lee J, Park YS, Lee SM, Yim JJ, et al. Lung cancer risk among patients with combined pulmonary fibrosis and emphysema. Respir Med 2014;108:524-30.
58. Lee T, Park JY, Lee HY, Cho YJ, Yoon HI, Lee JH, et al. Lung cancer in patients with idiopathic pulmonary fibrosis: clinical characteristics and impact on survival. Respir Med 2014;108: 1549-55.
59. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511:543-50.
60. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 2015;5:2892-911.
61. Park JY, Jang SH, Kim HJ, Park YB, Kwon JH, Song HH, et al. Predicting the treatment response using a direct sequencing method for EGFR in non-squamous, non-small cell lung cancer. Korean J Med 2011;81:611-22.
62. Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH. EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med 2009;24:48-54.
63. Kim HJ, Lee KY, Kim YC, Kim KS, Lee SY, Jang TW, et al. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Lung Cancer 2012;75:321-5.
64. Min KW, Kim WS, Jang SJ, Choi YD, Chang S, Jung SH, et al. Comparison of EGFR mutation detection between the tissue and cytology using direct sequencing, pyrosequencing and peptide nucleic acid clamping in lung adenocarcinoma: Korean multicentre study. QJM 2016;109:167-73.
65. Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, Xu X, et al. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol 2012;7:323-30.
66. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4 -ALK . J Clin Oncol 2009;27:4247-53.
67. Kang HJ, Lim HJ, Park JS, Cho YJ, Yoon HI, Chung JH, et al. Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma. Respir Med 2014;108:388-94.
68. Chia PL, Mitchell P, Dobrovic A, John T. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol 2014;6:423-32.
69. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561- 6.
70. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14: 4275-83.
71. Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist 2013;18:865-75.
72. Yoo SS, Jin G, Jung HJ, Hong MJ, Choi JE, Jeon HS, et al. RET fusion genes in Korean non-small cell lung cancer. J Korean Med Sci 2013;28:1555-8.
73. Bae EY, Lee SY, Kang BK, Lee EJ, Choi YY, Kang HG, et al. Replication of results of genome-wide association studies on lung cancer susceptibility loci in a Korean population. Respirology 2012;17:699-706.
74. Ahn MJ, Won HH, Lee J, Lee ST, Sun JM, Park YH, et al. The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations. Hum Genet 2012;131:365-72.